EGFR and kidney cancer: Several lines of evidence suggest that the significant down-regulation of EGFR observed in Ad5 E1-TC makes sense both in the context of kidney cells and lack of oncogenicity of this Ad serotype: over-expression of EGFR is associated with poor prognosis and metastatic spreading of renal cancer [62,63] and monoclonal anti-human EGFR antibody has been found to increase delay in tumorigenesis of human kidney cancer cell lines [64].